Icahn School of Medicine at Mount Sinai, New York (United States of America)
53
presentations
12
followers
4
more
presentations
in this session
The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction